Ley L

Department of Clinical Research, Division of Clinical Pharmacology & Toxicology, Psychopharmacology Research, University Hospital Basel, and University of Basel, Basel, Switzerland.

Ley L

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings.

Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment.

Psychedelics distinctly alter brain entropy and complexity compared to psychostimulants

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants.

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial.

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Safety pharmacology of acute mescaline administration in healthy participants.

Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.

Safety pharmacology of acute psilocybin administration in healthy participants.

The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.

Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration.

Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.

Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants.

The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity.

Liquid chromatography-tandem mass spectrometry method for the bioanalysis of N,N-dimethyltryptamine (DMT) and its metabolites DMT-N-oxide and indole-3-acetic acid in human plasma.

The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity

Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma.

Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.

Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants.

Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies.

MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens.

Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.

Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.